a b s t r a c t
The soft drug approach is successful in obtaining high local therapeutic efficacy without systemic adverse effects, because soft drugs are designed to be bioconverted to inactive form by hydrolytic enzymes in systemic circulation. However, there is little information about the exact nature of these metabolic enzymes. In this study, the human enzymes for biotransformation of soft drugs were investigated. Loteprednol etabonate (LE) and etiprednol dicloacetate (ED) were designed from D 1 -cortienic acid (D 1 -CA), the inactive metabolite of prednisolone, by introducing two labile ester bonds to restore the corticosteroidal activity. We found that LE and ED were mainly deactivated in human plasma rather than the liver. Inactive monoesters were produced, but the second hydrolysis to D 1 -CA was much slower. ED was hydrolyzed 10 times faster than LE in plasma (t 1/2 = 1.35 ± 0.08, 12.07 ± 0.52 h respectively). Paraoxonase 1 that attached with high density lipoprotein (HDL) was found to be the major hydrolase for LE and ED in human plasma as demonstrated by enzyme inhibition and stimulation experiments and the hydrolysis in lipoproteins-rich plasma fractions. Human serum albumin (HSA) showed slight hydrolase activity against ED but not LE. LE was slowly hydrolyzed in liver (clearance: 0.21 ± 0.04 and 2.41 ± 0.13 ml/h/ kg in liver and plasma, respectively) but ED wasn't hydrolyzed at all, so LE has superior metabolism in two sites. The difficult diffusion of HDL into tissues from blood suggests the stable presence of LE at the administration site, while ED might be deactivated by its relatively rapid chemical hydrolysis and hydrolase activity of HSA, in the interstitial fluid of the administration tissue. Moreover, deactivation in plasma and strong protein binding (around 98%) minimize the adverse effects of LE and ED in the systemic circulation.
Ó 2016 Elsevier Inc. All rights reserved.
Introduction
The 'Soft Drug' concept was developed in the late 1970s as a comprehensive, general methodology to design safer drugs based on drug metabolism. The general drug design principles, rules and classifications of different soft drugs (i.e. soft analogs, the inactive metabolite approach, the active metabolite approach, etc.) were outlined in 1980 together with examples of specific applications [1] . At the same time, a comprehensive new class of soft corticosteroids, based on the inactive metabolites derived from cortienic acid, substituted in the 17a-position with a unique carbonate and haloalkyl esters in the 17b-position were also developed. These molecules demonstrated remarkably high activities but low systemic side effects, thus providing a significantly improved therapeutic index. The progress of the soft drug field occurred rapidly and the concept became well established [2, 3] . One of the main and distinctive principles of the soft drug design is to avoid oxidative metabolic processes and replace them with hydrolytic processes based on the various esterases, since oxidative metabolic processes are slow, easily saturable and usually implicate drug interactions. This can be achieved by starting the design process with an inactive metabolite, formed by oxidative http://dx.doi.org/10.1016/j.bcp.2016.12.010 0006-2952/Ó 2016 Elsevier Inc. All rights reserved.
processes, often a carboxylic acid compound. Synthetic activation of this acid to an isosteric/isoelectronic analog of the given drug molecule provides the desired activity, but strategic design renders soft derivatives which are substrates to esterases, hydrolytic deactivation forms the inactive metabolite with which the design process started.
The design of the soft corticosteroids successfully led to FDA approved, clinically important novel safe drugs with unique properties such as loteprednol etabonate (LE) and etiprednol dicloacetate (ED), both were designed based on D 1 -CA (also called prednienic acid), an inactive metabolite of prednisolone. LE has ethyl carbonate ester and chloromethyl ester, while ED has dichloromethyl ester and ethyl ester at 17a-and 17b-positions, respectively [4] , as shown in Fig. 1 . The binding affinity of LE to glucocorticoid receptors is 4.3 times greater than that of dexamethasone [5] , but its therapeutic index (ratio of toxic and effective doses) is 24 times greater than those of most currently-used corticosteroids. The carbonate substitution at 17a-position prevents the formation of the mixed internal anhydride which is presumably cataractogenic [6] . The structure of LE, which prevents the formation of the cataractogenic moiety, makes it ideal for the treatment of ocular inflammation, and it has already been approved by the FDA for this use [5, 7] . In addition, a study was recently carried out to evaluate its potential in the treatment of rhinitis [8] . ED has a unique structure as it contains 17a-dichloroester, while no other known corticosteroid contains halogen substitution at the 17a-position. This structure improves the binding affinity of ED to glucocorticoid receptors to be even higher than that of LE [4] and provides fast hydrolysis of the ester bond [3] . ED was developed to be used mainly for the treatment of asthma [9] .
It is expected that LE and ED are spontaneously hydrolyzed to their inactive metabolites by several esterases in systemic circulation. The previous in vitro hydrolysis studies of LE showed half-life of 4.9 min in rat plasma, and in vivo pharmacokinetics studies in rats showed that LE was metabolized to the inactive monoester, D 1 -cortienic acid etabonate (the ''carboxyl metabolite"), which can be excreted in bile and urine or be further metabolized to D 1 -CA [10] . In dogs, the intact drug was undetectable in plasma after oral administration of LE, while only the carboxyl metabolite was detected but not D 1 -CA, suggesting its first pass hepatic metabolism to the inactive monoester [11] and very fast elimination of D 1 -CA. These data indicate the importance of plasma and hepatic hydrolases for the deactivation of LE. In spite of being already released to the market, no information was published about the actual metabolism and elimination of LE in humans. The metabolites of LE were not determined and only its half-life in plasma has been reported, half-life is 9.3 h of in vitro hydrolysis in plasma, and 2.2 h of in vivo elimination in plasma after intranasal administration [8, 12] . In case of ED, less information is available about the pharmacokinetics in experimental animals and humans. Concerning the hydrolysis of ED in human tissues, the available information is only that the incubation of ED with human serum decreases its pharmacological activity by converting it to the inactive hydroxyl metabolite [13] . The results of the previous studies suggest probable metabolism of LE and ED in liver and plasma. However, the organ(s) and the hydrolase enzyme(s) which are responsible for the deactivation of those two soft corticosteroids are not identified. Furthermore, the metabolites produced in human are not specified.
In this study, we aimed to clarify the deactivation process of LE and ED in the human body. We examined their in vitro hydrolysis in different human tissues and plasma. The enzyme involved in their deactivation process was identified by enzyme inhibition and stimulation experiments and hydrolysis experiment in lipoproteins-rich plasma fractions. Finally, in vivo metabolism process was discussed based on the tissue clearance predicted from in vitro data.
Materials and methods

Chemicals
LE, ED and their metabolites were kindly provided by Bodor Laboratories, Inc. (Miami, FL, USA). Paraoxon and eserine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Betamethasone valerate, betamethasone, 2-amino-2-hydroxymethyl-1,3-propane diole (Tris), polyethylene glycol 6000 (PEG 6000), triton X-100 and dimethyl sulphoxide (DMSO) were purchased from Wako pure chemicals (Osaka, Japan). 4-(2-Hydroxyethyl)-1-piperazineethane sulfonic acid (HEPES) was purchased from Dojindo molecular technology (Kumamoto, Japan). Ethylenediaminetetraacetic acid trisodium salt (EDTA) and calcium chloride dihydride were purchased from Nacali tesque (Kyoto, Japan). All other chemicals and reagents were purchased from Wako pure chemicals (Osaka, Japan) and were of analytical grade.
Biological materials
Three different human plasma pools were collected from ten healthy volunteers. Studies involving human plasma were approved by the Institutional Review Board of Kumamoto University, Faculty of Life Sciences. A written consent was signed by the healthy human volunteers prior to their participation in this study. Human liver and intestine S9 fractions of BD Gentest TM were obtained from Corning life sciences (Tewksbury, MA, USA). Human serum albumin (HSA) and bovine serum albumin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Protein content was determined in plasma pools and S9 fractions of liver and intestine by Bradford protein assay [14] using bovine serum albumin as a standard.
2.3. Hydrolysis in buffer, human plasma, HSA and different tissues LE, ED, carboxyl metabolite of LE, hydroxyl metabolite of ED and betamethasone valerate were dissolved in DMSO to be used as substrates. S9 fractions of human liver or intestine and HSA solutions were prepared to obtain the appropriate protein concentrations (100 lg/mL for S9 factions and 4, 20, 40 mg/mL for HSA). The prepared solutions and intact human plasma (200 lL) were preincubated at 37°C for 5 min. The reaction was initiated by the addition of 2 lL of the substrate dissolved in DMSO. The reaction was terminated by the addition of 400 lL of ice cold acetonitrile: methanol (1:1 v/v). After centrifugation of the reaction mixtures, the supernatants were analyzed by HPLC. In case of ED, 25% phosphoric acid (6 lL) was added to 400 lL of the supernatant to prevent the chemical hydrolysis. The hydrolysis velocities were measured under reaction conditions at which less than 10% of the substrate was hydrolyzed. All the results in S9 fractions and HSA solutions were calculated to subtract the chemical hydrolysis.
In the inhibition experiments in human plasma, three different enzyme inhibitors (paraoxon, eserine and EDTA) were preincubated with the plasma at 37°C for 5 min before the addition of the substrate. In case of paraoxon and eserine, 2 lL of the inhibitor solution in DMSO was preincubated with 198 lL of plasma, and EDTA 20 lL of aqueous solution was incubated with 180 lL of plasma. The control samples were prepared by the same way replacing the solution of each inhibitor by the solvent. The reaction mixtures were treated by the same procedure described above. In all hydrolysis experiments the concentration of DMSO was less than 1%. Only in the case of addition of EDTA, 25% phosphoric acid (6 lL) was added to the supernatant to precipitate EDTA to avoid the baseline noise during HPLC analysis, the supernatant obtained after further centrifugation was neutralized with 10% NaHCO 3 before injection to HPLC.
For the stimulating effect of calcium ion on the hydrolysis of LE and ED in human plasma, the plasma diluted to 10% by 50 mM HEPES buffered saline (pH 7.4) was incubated with the substrates at 37°C in the presence of various concentrations of calcium ion. and kept on ice for 15 min then centrifuged at 3000g for 15 min at 4°C. The precipitate was used as the first fraction (PPT1). The supernatant was well mixed with a solution (third the volume of the supernatant) containing 20% PEG 6000 and 200 mM glycine, pH 7.4 and kept on ice for 15 min then the precipitate was obtained by centrifugation at 3000g for 15 min at 4°C and used as the second fraction (PPT2). Each precipitate fraction (PPT1 and PPT2) was dissolved in 400 lL of 50 mM HEPES buffered saline (pH 7.4) containing 1 mM triton X-100 and 2 mM CaCl 2 , the protein content was determined by Bradford protein assay [14] using bovine serum albumin as standard. The presence of paraoxonase in each fraction was checked by native PAGE according to previous method [15] . Twenty-five microgram of protein was loaded to 6% w/w polyacrylamide gel. After electrophoresis, bands with hydrolase activity were visualized through the coupling of fast blue RR salt with bnaphthol liberated from the b-naphthyl acetate.
Hydrolysis of paraoxon, LE and ED in the lipoproteins-rich plasma fractions
The hydrolysis of paraoxon, LE and ED was determined in the solutions of PPT1 and PPT2 in 50 mM HEPES buffered saline containing 1 mM triton X-100 and 2 mM CaCl 2 , pH 7.4. Hydrolysis rates of LE and ED were determined using the same procedure mentioned under Section 2.3. replacing plasma with the solutions of PPT1 and PPT2. The hydrolysis rate of paraoxon was determined from the formation of p-nitrophenol [16] ; it was monitored for 10 min at 405 nm using Jasco V-630 spectrophotometer coupled with Jasco EHC-477T temperature controller. Hydrolysis velocities were measured under reaction conditions at which less than 10% of the substrate was hydrolyzed and the ratios of hydrolysis velocities in PPT1 and PPT2 (PPT2/PPT1) were calculated.
The inhibitory effect of LE and ED on the hydrolysis of paraoxon was determined in the solution of PPT2 (970 lL) preincubated with 10 lL LE and ED dissolved in DMSO (15 mM) for 1 min at 37°C. The reaction was initiated by addition of 20 lL of paraoxon aqueous solution (1.5 mM) and the concentration of p-nitrophenol converted from paraoxon was measured at 405 nm. In control LE and ED solutions were replaced by DMSO.
Quantification of LE, ED, betamethasone valerate and their metabolites
RP-HPLC was used for the simultaneous determination of each substrate and its metabolite. The HPLC system comprised a JASCO PU-980 pump, a JASCO PU-2080 plus pump, a JASCO 980-UV detector, a JASCO AS-2055 plus autosampler, a HITACHI 655A-52 column oven and a Shimadzu Chromatopac C-R7A plus (Shimadzu Co., Ltd., Kyoto, Japan). All separations were carried out on C 18 inertsil Ò ODS-3 column (150 mm Â 4.6 mm Â 4 lm) heated at 40°C. Gradient elution was used for all reaction mixtures of LE experiments. Mobile phase A was composed of 0.01% acetic acid solution: acetonitrile (50:50 v/v) and mobile phase B was composed of 0.03% acetic acid solution: acetonitrile (50:50 v/v), initial proportion of 100% A was kept for 2 min, followed by linear gradient to 100% B over the next 8 min, then 100% B was maintained for 5 min, finally mobile phase returned to 100% A by linear gradient over 10 min. Retention times of LE and its carboxyl metabolite were 17 and 9.8 min, respectively. For the experiment of the inhibition of ED hydrolysis with paraoxon also gradient elution was used. Mobile phase A was 0.05% acetic acid: acetonitrile: methanol (50:35:20 v/v/v) and mobile phase B was 0.5% acetic acid: acetonitrile: methanol (40:45:20 v/v/v). The mobile phase was 100% A for the first 12 min followed by linear gradient to 100% B over the next 18 min, then 100% B was kept for 5 min, finally mobile phase returned to 100% A by linear gradient over 5 min. Retention times of ED and its hydroxyl metabolites were 31 and 10.5 min, respectively. For all other experiments of ED and betamethasone valerate, isocratic elution was used. The mobile phase was 0.05% acetic acid: acetonitrile (55:45 v/v). The retention times were 37 and 8 min for ED and its hydroxyl metabolite, respectively, while the retention times of betamethasone valerate and betamethasone were 18 and 4.1 min, respectively. Detection wavelength was 245 nm and the flow rate was 1 mL/min in all experiments.
Data analysis
For each inhibition and stimulation experiment, control was set as 100%, and the amount of metabolite formed in the presence of an inhibitor or stimulator was expressed as percent of control. Half-lives of LE and ED in human plasma, HSA solution (4%) and phosphate buffer were determined from the relation between the natural logarithm of the remaining concentration of the substrate and the incubation time at 37°C. Intrinsic clearance was calculated from the slope of the plot of velocity against substrate concentration and tissue clearance was calculated based on well stirred model. The student's t-test was used to compare the activities and the analysis of variance (ANOVA) was performed to check the significance of differences in the means among groups. Table 1 shows the hydrolysis rates of LE, ED and betamethasone valerate in both liver and intestine S9 fractions. Betamethasone valerate was used as positive control; its hydrolysis rate was nearly same in both liver and intestine S9 fractions (357.2 ± 5.658 and 383.1 ± 13.37 pmol/min/mg protein, respectively). LE was also hydrolyzed in both S9 fractions, but its hydrolysis was markedly slow in comparison to betamethasone valerate. Interestingly, LE was hydrolyzed at a faster rate in intestinal S9 fraction than in hepatic S9 fraction, probably due to the presence of several digestive hydrolases in intestine. In contrast, ED was not hydrolyzed in intestine and liver S9 fractions; the hydrolysis of ED was not detected even after long incubation periods up to 8 h.
Results
Hydrolysis of LE, ED and betamethasone valerate
In human plasma, both LE and ED were hydrolyzed to give one monoester metabolite for each, the carboxyl metabolite and hydroxyl metabolite for LE and ED, respectively. As shown in Fig. 2 , the disappearance rates of LE and ED were the same as the formation rates of their monoester metabolites. The other monoester metabolites and D
1
-CA were not detected in plasma after the hydrolysis of LE and ED. The carboxyl metabolite of LE and the hydroxyl metabolite of ED were also not hydrolyzed in vitro by hepatic or intestinal S9 fractions ( Table 1 ).
The hydrolysis rates (calculated as metabolite formation rate) of both LE and ED linearly increased with their concentration in human plasma up to 150 lM of each, as shown in Fig. 2 . The limited solubility of LE and ED inhibited the determination of their hydrolysis rates at higher substrate concentrations until reaching enzyme saturation. The hydrolysis of ED in plasma was almost 10-folds faster than that of LE. The half-lives of LE and ED in human plasma were around five times shorter than their half-lives in phosphate buffered saline, pH 7.4 (Table 2), indicating protein mediated hydrolysis in plasma. Although HSA is the most abundant plasma protein with hydrolase activity against several substrates, the hydrolysis rates of LE and ED in 4% HSA solution, same HSA concentration as in plasma, were 87.1 ± 4.17 and 101.2 ± 1.56% of those in buffer, respectively. Those percentage shows that, HSA is not the main plasma protein responsible for LE and ED hydrolysis. All data represent the average and standard deviation of three different determinations.
Protein binding of LE and ED
Hydrolase activity was determined under reaction conditions of 20 lM substrate in S9 fraction (protein concentration100 lg/mL) at 37°C. a Significant difference from the hydrolase activity of betamethasone valerate (P < 0.01). b Significant difference from the hydrolase activity of LE in liver S9 fraction (P < 0.01).
(97.9 ± 0.36 and 98.7 ± 0.42% for LE and ED, respectively). If we consider the unbound drug in plasma (around 2%), the hydrolysis of LE and ED in plasma is much faster than their hydrolysis in buffer. ED binding to 4% HSA (the same concentration as in plasma) is almost as high as its binding to plasma proteins with a value of 97.4 ± 0.03%, while LE binding to HSA is significantly lower than its binding to plasma proteins (89.9 ± 1.3%), which shows the binding of LE not only to HSA but also to other plasma proteins such as lipoproteins. Table 3 shows the hydrolysis rates and the percentage of protein binding of LE and ED in different concentrations of HSA. The hydrolysis rates of LE and ED in 0.4% HSA solutions (the lowest tested concentration) were 92.9 ± 3.89 and 55.1 ± 2.37% of those in HEPES buffered saline, respectively. The slower hydrolysis in HSA solution might be due to the stabilization effect of protein binding which decreases the concentration of the free drug susceptible to the attack by the hydroxyl group. The increase of HSA concentration induced very small increase in the protein binding percentage of LE and ED. The hydrolysis rate of LE slightly decreased with the increase of HSA concentration as expected from the protein binding data but the hydrolysis rate of ED in 0.4% HSA was much slower than that in 4% HSA, which suggests the presence of hydrolase activity of HSA against ED. The hydrolase activity of HSA against ED and LE (20 lM), calculated from the linear relation between the hydrolysis rate and HSA concentration, was 0.46 ± 0.031 and À0.005 ± 0.001 pmol/min/mg, respectively.
Hydrolysis of LE and ED in HSA solutions
Effect of enzymes inhibition and stimulation on LE and ED hydrolysis in plasma
The main esterases in human plasma are paraoxonase 1 (PON1) and butyrylcholinesterase (BChE). The effect of inhibitors and stimulators for these enzymes was studied on the hydrolysis of LE and ED in human plasma. As shown in Table 4 , paraoxon (inhibitor for both PON1 and BChE) inhibited the hydrolysis of both LE and ED in a concentration dependent manner. The inhibition reached around 90% by 5 mM paraoxon. Eserine (inhibitor for BChE) showed no effect on the hydrolysis of both at concentrations up to 5 mM. EDTA (inhibitor for enzymes requiring metal ions) inhibited their hydrolysis in a concentration dependent manner. The highest inhibition by EDTA was around 50% and it was reached by 5 mM and 10 mM of EDTA with ED and LE, respectively. Increasing the concentration of calcium, which is essential for PON1 activity, stimulated the hydrolysis of both LE and ED in a concentration dependent manner. However, the stimulation of the hydrolysis All data represent the average and standard deviation of at least three different determinations. a Significant difference from the half-life in phosphate buffered saline (P < 0.01). b Significant difference from protein binding values in plasma (P < 0.01). 
mM). Those results
indicated that PON1 is the main enzyme responsible for the hydrolysis of LE and ED in human plasma.
Hydrolysis of LE and ED in lipoproteins-rich plasma fractions
Since PON1 is naturally associated with high density lipoproteins (HDL), lipoproteins-rich plasma fractions were prepared by precipitating plasma proteins using PEG 6000. Two lipoproteinrich plasma fractions were prepared by stepwise precipitation using increasing concentrations of PEG 6000. Each fraction had different content of PON1. Fig. 3 shows native PAGE of intact human plasma and the both lipoproteins-rich plasma fractions, PPT1 and PPT2. PON1, BChE and HSA can hydrolyze b-naphtyl acetate, so three clear bands were detected in intact human plasma. Alternately, PPT1 and PPT2 showed a clear band, with slowest mobility, of PON1 and very faint or no bands for HSA and BChE. The intensity of the PON1 band in PPT2 was stronger than that in PPT1. Table 5 shows the hydrolysis rates of each substrate (paraoxon, LE and ED) in each lipoproteins-rich plasma fraction in addition to the ratios of hydrolysis rates between PPT2 and PPT1. The hydrolysis rate of paraoxon in PPT2 was faster than its hydrolysis rate in PPT1 and their hydrolysis ratio (PPT2/PPT1) was 1.75 ± 0.12. The hydrolysis ratios for LE and ED in both lipoproteins-rich plasma fractions (PPT2 / PPT1) were found to be similar to that of paraoxon. Both ANOVA and student's t-test confirmed the similarity among the all ratios of hydrolysis for LE, ED and paraoxon. The results indicated that PON1, associated with HDL, is responsible for the enzymatic hydrolysis of LE and ED in human plasma. Fig. 4 shows the effect of the preincubation with LE and ED on the hydrolysis velocity of paraoxon (30 lM) in lipoproteins-rich plasma fraction (PPT2). LE and ED (150 lM) showed significant inhibition effect on the hydrolysis of paraoxon (around 60% and 65% for ED and LE, respectively). This inhibition effect also provides an evidence on the interaction of LE and ED with PON1.
Inhibitory effect of LE and ED on the hydrolysis of paraoxon
Discussion
Soft drugs are designed to have high local therapeutic effect with minimum systemic adverse effects. They should show strong pharmacological action at their administration site but should be deactivated in the systemic circulation. The complete deactivation of the soft drug by one step reaction in the systemic circulation minimizes the time spent by the active drug in the body. Blood and the liver are the most important metabolic sites in systemic circulation. However, the comparison of the hydrolysis of LE and Effect of Paraoxon and eserine was determined in 99% plasma and that of EDTA in 90% plasma. Effect of calcium ion was determined in 10% plasma diluted by HEPES buffered saline. Control experiment was carried out for each modifier under the same reaction conditions replacing the modifier with the solvent and the value was set as 100%. * Significant difference from the control value (P < 0.05). Table 5 Hydrolysis activities of LE, ED and paraoxon in the lipoproteins-rich plasma fractions (PPT1 and PPT2).
Plasma
Hydrolase activity in PPT1 Hydrolase activity in PPT2 Activity ratio PPT2/PPT1 Student's t-test ANOVA (F)
Paraoxon (nmol/min/mg) 2.11 ± 0. All data represent the average and standard deviation of at least three different determinations.
Substrate concentrations were 1 mM for Paraoxon, 20 lM for ED and 100 lM LE.
a Comparison with the activity ratio of paraoxon (tabulated t value is 1.895). b ANOVA among the activity ratios of paraoxon, LE and ED (F critical is 4.260).
ED to that of betamethasone valerate indicated that LE and ED were hardly deactivated in vitro in human liver S9 fraction, and even in the intestinal S9 fraction which contains various esterases for digestion. Betamethasone valerate was selected as a positive control to check the hydrolase activity of the used S9 fractions, because it is structurally related to LE and ED. Betamethasone valerate is a corticosteroid containing an ester bond at 17a-position, and it is proved to be hydrolysable in hepatic and intestinal S9 fractions, similar to previous report about the hydrolysis in microsomal fractions [17] . LE and ED were found to be hydrolyzed to their inactive monoester metabolites in human plasma; carboxyl metabolite and hydroxyl metabolite for LE and ED, respectively. These monoester metabolites could be possibly taken up in the liver; however, the monoester metabolites were also not hydrolyzed in hepatic S9 fraction. The major esterase in the liver and intestine is carboxylesterase that catalyzes various exogenous compounds including betamethasone valerate [17, 18] . In contrast, carboxylesterase hardly hydrolyzes LE, ED and their monoester metabolites. These observations suggest that corticosteroids with an ester bond on the 17b-position are difficult to be hydrolyzed by carboxylesterase. Although the carboxyl monoester metabolite of LE keeps an ester bond on the 17a-position like betamethasone valerate, it has not been hydrolyzed by carboxylesterase, probably due to carboxyl acid form such as aceclofenac [19] . Since carboxylesterase is the most abundant esterase in several organs, being unsusceptible to hydrolysis by carboxylesterases suggests the stability of LE and ED in several tissues. In plasma, only the monoesters metabolites of LE and ED were found, but D 1 -CA was not observed. In the additional experiment to confirm the stability of the monoesters in human plasma, the carboxyl metabolite of LE and the hydroxyl metabolite of ED, used as substrates, were not hydrolyzed (unpublished data). The stability of the monoester metabolites in human plasma and the different tissues indicates that they are the final metabolites in the human body. Thus, conversion to inactive and stable metabolites by one step reaction is the ideal behavior of soft drugs. Blood is the first tissue that gets in contact with the soft drug after removal from the application site, so the recent research has been directed to produce soft drugs which can be deactivated in blood rather than the liver or other organs [20] . Hydrolysis of ED in human plasma was found to be almost 10 times faster than the hydrolysis of LE. This was expected because ED is belonging to a group of soft corticosteroids which has dichlorinated substitution at 17a-position of D 1 -CA. This structure increases the rate of hydrolysis by several times [4] . The fast hydrolysis of ED in plasma should be better for safety. However, the slow hydrolysis of ED by HSA, which presents in the interstitial fluids, and its relatively fast chemical hydrolysis (around 8.5-folds faster than LE) may represent a disadvantage from the point of stability at the administration site. In contrast, LE would be more stable at the administration site because of its slow chemical hydrolysis and the stabilization by HSA.
The results of enzymes inhibition and stimulation experiments in plasma and the hydrolysis of LE and ED in lipoproteins-rich plasma fractions demonstrated that the hydrolysis of LE and ED in human plasma is mediated by PON1, not BChE. In addition, purified human BChE was inactive to hydrolyze LE or ED (unpublished data). The active site of BChE is similar to that of carboxylesterases; both belong to serine esterases which have an active site depending on a catalytic triade formed from serine, histidine and glutamate [18] . However, the active site of PON1 is different. It uses a catalytic diade formed of two histidine moieties and requires two calcium ions for the activity. One of the calcium ions is functional, stabilizes the intermediate oxyanionic moiety, and the other is structural [21] . Sequestering those calcium ions with EDTA decreases or abolishes the hydrolase activity of PON1 [22] , while the addition of calcium ions stimulates it. In the inhibition study, paraoxon, which directly interacts with the active center of PON1, showed complete inhibition. However, the capture of calcium ion by EDTA in plasma showed incomplete inhibition and the stimulatory effect of the addition of calcium ions was also limited, due to the physiological presence of Ca 2+ and Mg 2+ in plasma.
The divalent metal ions in plasma compete with the calcium ions of PON1 for EDTA. The concentration of the endogenous calcium is high enough for the enzyme activity which minimizes the stimulatory effect of the added calcium, even when the plasma is diluted the calcium binding proteins, such as HSA, liberate more calcium keeping the effect of the added calcium weak. It has been reported that phosphate ion is present in the active site of PON1 and it plays a role in the positioning of the functional calcium ion [21] . In fact, dilution of plasma with phosphate buffer caused faster hydrolysis rates of LE and ED comparing to the dilution with HEPES buffer. (Unpublished data). The hydrolysis effect of PON1 against LE and ED was studied in the lipoproteins-rich plasma fractions which showed almost no hydrolase activity for HSA and BChE. The usage of lipoproteinsrich plasma fractions allows the characterization of PON1 as it is in vivo, which permits the analysis of the exact interaction between the drugs and PON1. The attachment of PON1 to HDL would facilitate an interaction of lipophilic drugs. LE and ED were hydrolyzed in the two lipoproteins-rich plasma fractions and their hydrolysis ratios in the two fractions were nearly the same as that of paraoxon. In addition, the hydrolysis of paraoxon was inhibited by LE and ED. These data strongly support the responsibility of PON1 for the hydrolysis of LE and ED.
PON1 activity is known to be almost exclusive in plasma, while its activity in tissues other than plasma is absent [20] .The attachment of PON1 to HDL, which has relative large particle size (7.3-14 nm), hinders its diffusion to tissues. As a result, soft drugs that are deactivated by PON1 will remain active as long as they stay at the application site and will be deactivated as soon as they reach the plasma. This metabolic behavior is ideal for soft drugs.
The strong protein binding of LE and ED in plasma also has a remarkable effect on their pharmacokinetics. This is probably the reason of not reaching the saturation of the hydrolysis reaction in plasma until high concentrations (150 lM), because the free drug concentration is much lower. LE was proved to have no effect on the endogenous cortisol level in human after intranasal administration for 14 days [8] , in spite of its high lipophilicity which allows it to pass the blood brain barrier. This is due to not only the deactivation in plasma by PON1 but also the strong protein binding which makes the free concentration of the drug too low to affect the endogenous cortisol level. Although HSA is the major protein for binding with LE and ED, the protein binding of LE to HSA was significantly less than its binding to plasma proteins. So, LE might bind to other plasma proteins, like lipoproteins, due to its high hydrophobicity (log P 3.04). On the other hand, ED doesn't show such a difference in its protein binding to HSA and plasma proteins, in spite of having almost the same log P value (2.98). These differences in the protein binding profile between LE and ED can affect their interaction with plasma hydrolases; for example, LE is expected to have better interaction with PON1, which is naturally associated to HDL and that should facilitate its plasma deactivation. Moreover, the strong binding to HSA would help in keeping the drug at the administration tissue for longer period due to the presence of HSA in the interstitial fluid of the tissues. So the protein binding profile of LE would keep it for long time at the administration site which would potentiate its activity and would help its deactivation in plasma which potentiates its safety.
Various clinical uses of LE could not detect any systemic adverse effects. The effect of the slow hydrolysis of LE in human liver on its elimination was also considered. The hepatic clearance was estimated from the intrinsic clearance by liver S9 fraction considering the well stirred model [23] . Scaling was made using the S9 protein content in human liver and the weight of liver per body weight [24, 25] . The estimated hepatic clearance is 0.21 mL/h/kg. The estimated plasma clearance using the mean plasma volume in the adult body is 2.41 mL/h/kg. Although hepatic clearance is 11 times slower than plasma clearance, hepatic deactivation of LE can enhance the safety, especially if LE is administered by inhalation, because most of the dose of the inhaled drugs (60-90%) inters the gastrointestinal tract [20] , or if it is used by patients having plasma esterases with reduced activity, such as diabetic patients who are usually suffering from impaired PON1activity.
In conclusion, LE and ED are deactivated mainly in human plasma rather than in the liver. Deactivation of LE and ED in human plasma is mediated by PON1 which is attached to HDL, so those soft drugs will be relatively stable at their application sites. ED has an advantage of around 10-folds faster hydrolysis in human plasma which should be better for safety. However, rapid chemical hydrolysis of ED, together with the HSA hydrolase activity against it, might affect its stability at the administration site. The design of LE has some advantages such as; the high affinity to lipoproteins, the additional deactivation in the liver and the absence of HSA hydrolase activity against it. So, continuous research is required to improve the benefit to risk ratio of soft drugs. This work will help in designing better soft drugs with larger therapeutic windows. It will also help the researchers to target PON1 as an advantageous deactivation enzyme from an early stage of soft drug designing.
